Enrollment Eligibility Expanded to Include Human Leukocyte Antigen A24 or A26 Positive Patients PORTLAND, Ore., March 26, 2015 (GLOBE NEWSWIRE)... ...http://www.bizwireexpress.com/showstoryGNW.php?storyid=64882
- Conclusions Support Registration Strategy Including NASH Cirrhosis - - Detailed Data to be Presented in Late-Breaker Poster at EASL Meeting - SAN... ...http://www.bizwireexpress.com/showstoryGNW.php?storyid=64879
Significant Progress Made in Building a Global Specialty Therapeutics Company Conference Call to be Held on 26 March 2015 at 2.00 p.m. CET / 9.00... ...http://www.bizwireexpress.com/showstoryGNW.php?storyid=64867
Stryker Corporation's Spine Division announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the... ...http://www.asianhhm.com/pressreleases/stryker-spine-receives-fda-clearance-for-new-lumbar-plating-system
La Jolla Pharmaceutical Company, a leader in the development of innovative therapies intended to significantly improve outcomes in patients... ...http://www.pharmabiz.com/NewsDetails.aspx?aid=87387&sid=2
An additional reason precisely why...